Jump Financial’s PharmaCyte Biotech PMCB Stock Holding History

Jump Financial’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,300	Closed	-$26K	–	1826
2021 Q4	$26K	Buy	+10,300	New	+$28.4K	﹤0.01%	1329

Other funds holding PMCB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's PMCB Position: Q1 2022 in Review

Jump Financial sold out of PharmaCyte Biotech (PMCB) in Q1 2022, closing a stake of 10,300 shares — an estimated $26K sold.

Jump Financial first reported a position in PMCB in Q4 2021 and held it in 1 quarter. The position peaked at $26K in Q4 2021. 25 funds tracked by Wall St. Rank hold PMCB as of Q1 2022.

Jump Financial reported no remaining PharmaCyte Biotech position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 10,300 PharmaCyte Biotech shares in Q1 2022, an estimated $26K.
Jump Financial first reported a position in PharmaCyte Biotech in Q4 2021 and held it in 1 quarter.
Jump Financial's PharmaCyte Biotech position peaked at $26K in Q4 2021.
25 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.